← All trials
NCT04788745
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 29, 2021
- Primary completion
- Sep 30, 2022
- Completion date
- Mar 31, 2023
- First posted
- Mar 9, 2021
- Last posted
- Aug 25, 2021
- Enrollment
- 36
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of QueenslandLead sponsor
- Utrecht UniversityOverall official - principal investigator
- Utrecht UniversityCollaborator
- University of QueenslandOverall official - principal investigator
- University of LondonOverall official - principal investigator
- University of LondonCollaborator
- Julius Clinical, The NetherlandsCollaborator
- Royal Brisbane & Women's HospitalOverall official - principal investigator
- FightMNDCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.